About Windtree Therapeutics (OTCMKTS:WINT)
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Industry, Sector and Symbol
SymbolOTCMKTS:WINTPrevious Symbol: NASDAQ:WINT
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$2.04 million
Price / Sales2.67
Price / CashN/A
Book Value($2.68) per share
Price / Book-0.15
Return on EquityN/A
Return on Assets-345.52%
Frequently Asked Questions for Windtree Therapeutics (OTCMKTS:WINT)
What is Windtree Therapeutics' stock symbol?
Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."
How were Windtree Therapeutics' earnings last quarter?
Windtree Therapeutics, Inc. (OTCMKTS:WINT) posted its quarterly earnings data on Monday, August, 21st. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.23. The biotechnology company had revenue of $1.15 million for the quarter, compared to analysts' expectations of $0.40 million. View Windtree Therapeutics' Earnings History.
Who are some of Windtree Therapeutics' key competitors?
Some companies that are related to Windtree Therapeutics include Senestech (SNES), Acura Pharmaceuticals (ACUR), Bio Blast Pharma (ORPN), ESSA Pharma (EPIX), Dextera Surgical (DXTR), Avinger (AVGR), Mateon Therapeutics (MATN), Lombard Medical (EVARF), Secure Point Technologies (IMSC), Strata Skin Sciences (SSKN), Roka Bioscience (ROKA), NeuroMetrix (NURO), TearLab Corporation (TEAR), Rosetta Genomics (ROSG), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), Delcath Systems (DCTHD) and BG Medicine (BGMD).
Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the folowing people:
- John R. Leone, Independent Chairman of the Board (Age 67)
- Craig Fraser, President, Chief Executive Officer, Director (Age 51)
- John A. Tattory, Chief Financial Officer, Senior Vice President (Age 49)
- Mary B. Templeton Esq., Senior Vice President, General Counsel and Corporate Secretary (Age 68)
- Kathryn A. Cole, Senior Vice President - Human Resources (Age 49)
- Steven G. Simonson M.D., Senior Vice President and Chief Development Officer (Age 56)
- William C. Roberts, Vice President - Investor Relations and Corporate Communications (Age 45)
- Michael L. Magee, Vice President - Technical Operations (Age 54)
- Mahady M. Joseph, Independent Director (Age 63)
- Bruce A. Peacock, Independent Director (Age 65)
How do I buy Windtree Therapeutics stock?
Shares of Windtree Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Windtree Therapeutics' stock price today?
One share of Windtree Therapeutics stock can currently be purchased for approximately $0.39.
How big of a company is Windtree Therapeutics?
Windtree Therapeutics has a market capitalization of $4.77 million and generates $2.04 million in revenue each year. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Windtree Therapeutics employs 49 workers across the globe.
How can I contact Windtree Therapeutics?
Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]
MarketBeat Community Rating for Windtree Therapeutics (WINT)MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Windtree Therapeutics (OTCMKTS:WINT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Windtree Therapeutics (OTCMKTS:WINT)
Analysts' Ratings History for Windtree Therapeutics (OTCMKTS:WINT)
(Data available from 11/23/2015 forward)
|6/30/2017||Stifel Nicolaus||Downgrade||Buy -> Hold|
|10/30/2016||HC Wainwright||Set Price Target||Buy||$8.00|
Earnings History and Estimates Chart for Windtree Therapeutics (OTCMKTS:WINT)
Earnings History by Quarter for Windtree Therapeutics (OTCMKTS WINT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/21/2017||Q2 2017||($0.99)||($0.76)||$0.40 million||$1.15 million||View||N/A|
|5/15/2017||Q1 2017||($1.37)||$0.22 million||View||N/A|
|8/10/2016||Q2||($1.64)||($1.29)||$0.08 million||$0.11 million||View||N/A|
|3/24/2016||Q4||($0.70)||($1.26)||$0.07 million||$0.66 million||View||Listen|
|8/10/2015||Q215||($0.13)||($0.13)||$0.45 million||$0.08 million||View||Listen|
|3/16/2015||Q414||($0.14)||($0.12)||$0.54 million||$1.18 million||View||N/A|
|11/6/2014||($0.15)||($0.13)||$0.50 million||$0.53 million||View||N/A|
|8/5/2014||Q2 14||($0.15)||($0.12)||$0.26 million||$1.09 million||View||N/A|
|5/8/2014||Q114||($0.13)||($0.14)||$2.69 million||$0.03 million||View||N/A|
|3/13/2014||Q413||($0.16)||($0.16)||$0.36 million||$0.07 million||View||N/A|
|8/8/2013||Q2 2013||($0.28)||($0.18)||$10.00 million||$0.18 million||View||N/A|
Earnings Estimates for Windtree Therapeutics (OTCMKTS:WINT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Windtree Therapeutics (OTCMKTS:WINT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Windtree Therapeutics (OTCMKTS WINT)
Insider Ownership Percentage: 3.45%
Institutional Ownership Percentage: 2.70%
Insider Trades by Quarter for Windtree Therapeutics (OTCMKTS WINT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/28/2016||Craig Fraser||Insider||Buy||7,500||$2.05||$15,375.00|| |
|2/19/2013||John R Leone||Director||Buy||3,000||$2.88||$8,640.00|| |
Latest Headlines for Windtree Therapeutics (OTCMKTS WINT)
Windtree Therapeutics (OTCMKTS WINT) Chart for Thursday, November, 23, 2017